Collaboration Agreements (Tables)

12 Months Ended

Jan. 01, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Collaborative Revenues Under Collaboration Agreement

Revenues under the collaboration agreement with Ipsen were as follows (in thousands):


	Year Ended December 31,
		2020		2019		2018
License revenues		$	93,495	$	117,360	$	157,569
Collaboration services revenues		58,136		35,411		25,310
Total		$	151,631	$	152,771	$	182,879

Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):


	Year Ended December 31,
		2020		2019		2018
License revenues		$	61,115	$	18,112	$	9,055
Collaboration services revenues		20,557		6,510		8,965
Total collaboration revenues		$	81,672	$	24,622	$	18,020

Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):


	Year Ended December 31,
		2020		2019		2018
Profits on U.S. commercialization		$	6,261	$	4,615	$	8,084
Royalty revenues on ex-U.S. sales		$	5,079	$	5,679	$	5,564